Rigel Pharmaceuticals (RIGL) EBIT Margin (2010 - 2026)
Rigel Pharmaceuticals (RIGL) recorded quarterly EBIT Margin of 20.21% in Q1 2026, down 39.13% quarter-over-quarter from 33.19% in Q4 2025, and down 374.0% on a YoY basis from 7.37% in Q1 2025.
Rigel Pharmaceuticals (RIGL) EBIT Margin (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' EBIT Margin history runs 16 years deep, the most recent figure standing at 20.21% for Q1 2026.
- In Q1 2026, EBIT Margin fell 374.0% year-over-year to 20.21%; the TTM figure through Mar 2026 stood at 41.56% (up 1993.0% YoY), while the FY2025 annual figure was 42.63%, up 2914.0% from the prior year.
- EBIT Margin was 20.21% for Q1 2026 at Rigel Pharmaceuticals, down from 33.19% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 60.09% in Q2 2025 to a low of 156.92% in Q1 2022.
- Historically, EBIT Margin has averaged 8.64% across 5 years, with a median of 4.05% in 2022.
- Biggest YoY gain for EBIT Margin was 10900 bps in 2022; the steepest drop was 20846 bps in 2022.
- A 5-year view of EBIT Margin shows it stood at 4.05% in 2022, then surged by 35 bps to 5.49% in 2023, then surged by 426 bps to 28.92% in 2024, then advanced by 15 bps to 33.19% in 2025, then tumbled by 39 bps to 20.21% in 2026.
- The last three EBIT Margin figures came in at 20.21% (Q1 2026), 33.19% (Q4 2025), and 40.91% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 603.18 Mn | 456.49 Mn | 54.21 Mn | 20.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.21% |
| Dec 31, 2025 | 33.19% |
| Sep 30, 2025 | 40.91% |
| Jun 30, 2025 | 60.09% |
| Mar 31, 2025 | 23.95% |
| Dec 31, 2024 | 28.92% |
| Sep 30, 2024 | 25.41% |
| Jun 30, 2024 | 1.21% |
| Mar 31, 2024 | -23.59% |
| Dec 31, 2023 | 5.49% |
| Sep 30, 2023 | -15.87% |
| Jun 30, 2023 | -19.59% |
| Mar 31, 2023 | -48.81% |
| Dec 31, 2022 | 4.05% |
| Sep 30, 2022 | -82.12% |
| Jun 30, 2022 | -43.48% |
| Mar 31, 2022 | -156.92% |
| Dec 31, 2021 | -104.94% |
| Sep 30, 2021 | -91.84% |
| Jun 30, 2021 | -49.68% |